文献速递核素与放射性配体治疗肿瘤 PET/CT

去势抵抗性转移性前列腺癌接受多周期[177Lu]Lu-PSMA-617放射性配体治疗的总生存与缓解模式

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-05-09

研究评估去势抵抗性前列腺癌患者接受至少三周期[177Lu]Lu-PSMA-617放射性配体治疗后的缓解模式及总生存。52例患者共接受190个周期治疗,第一周期后80.8%出现PSA下降、44.2%下降≥50%;第一周期无缓解者中50%在第二或第三周期出现缓解。第一周期后任何PSA下降者中位总生存显著长于无下降者(68 vs 33周)。

要点

  • 第一周期后80.8%患者PSA下降,44.2%下降≥50%;第三周期后73.1%较基线下降。
  • 第一周期无缓解者中50%在第二或第三周期出现缓解。
  • 第一周期后任何PSA下降者中位总生存显著长于无下降者(68 vs 33周)。

核心结论

  • 对放射性配体治疗有阳性缓解的患者,无论PSA下降幅度如何,中位总生存均显著更长。
  • 第一周期无任何缓解的患者中,50%在第二或第三周期出现缓解。

研究设计与样本

  • 去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617放射性配体治疗,每周期中位间隔8周。
  • 共52例患者接受190个周期治疗,每例3-6个周期。
  • 以肿瘤标志物前列腺特异性抗原(PSA)作为缓解评价指标。

主要发现

  • 第一周期后2个月,80.8%患者PSA下降,其中44.2%下降≥50%。
  • 与基线PSA相比,第三周期后73.1%患者PSA下降。
  • 第一周期无缓解的患者中,50%对第二和第三周期也无缓解。
  • 全部患者中位总生存为60周。
  • 第一周期后任何PSA下降者中位总生存显著长于无PSA下降者(68 vs 33周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Up to 30% of patients with castration-resistant prostate cancer (CRPC) do not show any response to the first cycle of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 (Lu-PSMA). We evaluated patient response to the second and third cycles of RLT in patients that underwent at least three cycles. The second aim of this study was to calculate the median overall survival (OS) of responders and non-responders after the first cycle and after all three cycles of RLT. METHODS: CRPC patients were treated with Lu-PSMA, with a median interval of 8 weeks between each cycle. The tumour marker prostate-specific antigen (PSA) was used as the marker for response evaluation. RESULTS: Fifty-two patients underwent a total of 190 cycles of RLT (3-6 cycles per patient). Of these, 80.8% showed a decline in PSA 2 months after the first cycle, with 44.2% showing a PSA decline of ≥50%. When compared to baseline PSA, 73.1% showed a PSA decline after the third cycle. 50% of patients that did not show any response to the first cycle also did not respond to the second and third cycles. The median OS was 60 weeks in all patients. The median OS was significantly longer for patients that showed any PSA decline after the first cycle compared to patients without PSA decline (68 vs. 33 weeks). There was a significant difference in median OS between responders and non-responders for a change in PSA after the third cycle compared to baseline PSA. CONCLUSION: Patients with a positive response to RLT, regardless of the rate of decline, had a significantly longer median OS. Of the patients that did not show any response to the first cycle, 50% responded to the second or third cycles.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ahmadzadehfar H, Wegen S, Yordanova A, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017. PMID: 28488028. doi:10.1007/s00259-017-3716-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。